Patent · US Active

Prevention of pertussis using adenylate cyclase deficient Bordetella strains

US10369207B2 · kind B2 · utility

1Cited by

2References

10Claims

0Family size

Assignees

NATIONAL UNIVERSITY OF SINGAPORE · SG
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
INSTITUT PASTEUR DE LILLE · FR

Inventors

Sylvie Claudette Alonso · Singapore, SG
Annabelle Rui Fen Lim · Singapore, SG
Camille Locht · Wannehain, FR

Key dates

Filing date	Jul 12, 2018
Grant date	Aug 6, 2019
Priority date	—
Expiry date	Jul 12, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/522
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.